stockportfolio.pro
Natera, Inc. (NTRA)
Healthcare · Diagnostics & Research · NasdaqGS
Natera, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $217.07M | $210.94M | $257.65M | $302.33M | $391.00M | $625.49M | $820.22M | $1.08B | $1.70B | $2.31B |
| Gross profit | $82.58M | $75.43M | $99.57M | — | — | — | $363.97M | $492.74M | $1.02B | $1.49B |
| Net income | $-100.33M | $-137.63M | $-128.15M | $-124.83M | $-229.74M | $-471.72M | $-547.80M | $-434.80M | $-190.43M | $-208.16M |
| Net margin | -46.2% | -65.2% | -49.7% | -41.3% | -58.8% | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
Source: Natera, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
What growth is priced into NTRA stock?
At today's market cap of $31.01B, Natera, Inc. is priced for free-cash-flow growth of about 51% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $76.11M from the FY ending 2025-12-31). For comparison, revenue 42.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 13 years of Natera, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NTRA in your portfolio →
Natera, Inc. financial history by metric
About Natera, Inc.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Natera, Inc. — frequently asked questions
What is Natera, Inc.'s revenue?
Natera, Inc. (NTRA) reported revenue of $2.31B for fiscal year 2025, up 35.9% from the prior year, according to its SEC filings.
Is Natera, Inc. profitable?
No — NTRA reported a net loss of $-208.16M in fiscal 2025.
What is NTRA's P/E ratio?
Natera, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Natera, Inc. growing?
NTRA's revenue grew at roughly 42.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Natera, Inc. have?
As of fiscal year 2025, NTRA carried roughly $80.32M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Natera, Inc.'s gross margin?
NTRA's gross margin was 64.7% in fiscal 2025 — gross profit of $1.49B on revenue of $2.31B.
What is Natera, Inc.'s market cap?
Natera, Inc. (NTRA) has a market capitalization of about $31.01B, based on the latest data in our nightly-refreshed cache.
When does Natera, Inc.'s fiscal year end?
NTRA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into NTRA stock?
At today's market cap of $31.01B, Natera, Inc. is priced for free-cash-flow growth of about 51% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $76.11M from the FY ending 2025-12-31). For comparison, revenue 42.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Natera, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.